Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.36 - $0.49 $3,744 - $5,096
-10,400 Reduced 91.23%
1,000 $0
Q3 2022

Nov 14, 2022

SELL
$0.45 - $0.69 $1,890 - $2,898
-4,200 Reduced 26.92%
11,400 $6,000

Others Institutions Holding ORTX

About Orchard Therapeutics plc


  • Ticker ORTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,458,000
  • Description
  • Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...
More about ORTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.